指南与共识骨软组织肉瘤与黑色素瘤

欧洲基于共识的侵袭性皮肤鳞状细胞癌跨学科指南:第2部分 治疗-2023更新

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
指南 / 共识 · Eur J Cancer · 2023-07-28

欧洲多学科专家组基于证据文献综述、指南和专家共识更新侵袭性皮肤鳞状细胞癌的治疗建议。涵盖常见原发(低危、高危)、局部晚期、区域转移(可手术或不可手术)及远处转移cSCC的治疗。手术切缘阴性是手术可及患者最重要的治疗考量;抗PD-1药物为晚期cSCC一线系统治疗。

要点

  • 常见原发cSCC一线治疗为手术切除加术后切缘评估或显微控制手术。
  • 高危局部cSCC切缘阴性者,辅助放疗现有证据未显示显著获益。
  • 晚期cSCC一线系统治疗为抗PD-1药物,西米普利单抗为首个获批药物。

核心结论

  • 常见原发cSCC一线治疗为手术切除加术后切缘评估或显微控制手术,实现清晰手术切缘是最重要的治疗考量。
  • 高危局部cSCC切缘阴性者,辅助放疗现有证据未显示显著获益。
  • 不可手术或放疗的晚期cSCC患者,抗PD-1药物为一线系统治疗。
  • 晚期cSCC所有患者必须经多学科委员会决策,并参与知情共享决策。

研究设计与样本

  • 由EADO、EDF、ESTRO、UEMS、EADV和EORTC组成多学科专家组制定。
  • 建议基于证据文献综述、指南和专家共识。

主要发现

  • 常见原发cSCC一线治疗为手术切除加术后切缘评估或显微控制手术。
  • 高危局部cSCC切缘阴性者,辅助放疗现有证据未显示显著获益。
  • 放疗应考虑作为不可手术候选者/肿瘤的主要治疗。
  • 细胞学或组织学证实区域淋巴结转移的cSCC推荐行淋巴结清扫。
  • 不可治愈手术或放疗的转移性或局部晚期cSCC,抗PD-1药物为一线系统治疗,西米普利单抗为FDA/EMA首个获批晚期cSCC系统药物。

关键数值与推荐

  • 常见原发cSCC(低危、高危)一线治疗:手术切除加术后切缘评估或显微控制手术。
  • 高危局部cSCC切缘阴性者:辅助放疗现有证据未显示显著获益。
  • 不可手术候选者/肿瘤:放疗应考虑作为主要治疗。
  • 区域淋巴结转移(细胞学或组织学证实):推荐淋巴结清扫。
  • 晚期cSCC二线系统治疗包括表皮生长因子受体抑制剂(西妥昔单抗)联合化疗或放疗。

临床怎么用

  • 常见原发cSCC首选手术切除加术后切缘评估或显微控制手术。
  • 不可手术候选者/肿瘤可考虑放疗作为主要治疗。
  • 区域淋巴结转移者推荐淋巴结清扫。
  • 晚期cSCC一线系统治疗为抗PD-1药物,二线包括西妥昔单抗联合化疗或放疗。
  • 晚期cSCC所有患者必须经多学科委员会决策,考虑毒性风险、年龄、衰弱及合并症(包括免疫抑制),并提供最佳支持治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In order to update recommendations on treatment, supportive care, education, and follow-up of patients with invasive cutaneous squamous cell carcinoma (cSCC), a multidisciplinary panel of experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV), and the European Organisation of Research and Treatment of Cancer (EORTC) was formed. Recommendations were based on an evidence-based literature review, guidelines, and expert consensus. Treatment recommendations are presented for common primary cSCC (low risk, high risk), locally advanced cSCC, regional metastatic cSCC (operable or inoperable), and distant metastatic cSCC. For common primary cSCC, the first-line treatment is surgical excision with postoperative margin assessment or micrographically controlled surgery. Achieving clear surgical margins is the most important treatment consideration for patients with cSCCs amenable to surgery. Regarding adjuvant radiotherapy for patients with high-risk localised cSCC with clear surgical margins, current evidence has not shown significant benefit for those with at least one high-risk factor. Radiotherapy should be considered as the primary treatment for non-surgical candidates/tumours. For cSCC with cytologically or histologically confirmed regional nodal metastasis, lymph node dissection is recommended. For patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiotherapy, anti-PD-1 agents are the first-line systemic treatment, with cemiplimab being the first approved systemic agent for advanced cSCC by the Food and Drugs Administration/European Medicines Agency. Second-line systemic treatments for advanced cSCC, include epidermal growth factor receptor inhibitors (cetuximab) combined with chemotherapy or radiotherapy. Multidisciplinary board decisions are mandatory for all patients with advanced cSCC, considering the risks of toxicity, the age and frailty of patients, and co-morbidities, including immunosuppression. Patients should be engaged in informed, shared decision-making on management and be provided with the best supportive care to improve symptom management and quality of life. The frequency of follow-up visits and investigations for subsequent new cSCC depends on underlying risk characteristics.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023. Eur J Cancer. 2023. PMID: 37708630. doi:10.1016/j.ejca.2023.113252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。